Xiangning Huang

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Roy S. Herbst, Yi‐Long Wu, Thomas John et al. · Journal of Clinical Oncology · 2023 · 389 citations · Full text

Medicine, Oncology, Pharmacology +17

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

Florian Wagenlehner, Jack D. Sobel, Paul Newell et al. · Clinical Infectious Diseases · 2016 · 352 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +17

Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLC

Shun Lu, Terufumi Kato, Xiaorong Dong et al. · New England Journal of Medicine · 2024 · 295 citations

Medicine, Oncology, Pharmacology +15

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis

Myung‐Ju Ahn, Chao‐Hua Chiu, Ying Cheng et al. · Journal of Thoracic Oncology · 2019 · 169 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Ying Cheng, Yong He, Wěi Li et al. · Targeted Oncology · 2021 · 162 citations · Full text

Medicine, Oncology, Pharmacology +17